| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/13/2001 | WO2001094307A1 Propanolaminotetralines, preparation thereof and compositions containing same |
| 12/13/2001 | WO2001094301A2 Factor viia inhibitory (thio)urea derivatives, their preparation and their use |
| 12/13/2001 | WO2001094300A1 Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament |
| 12/13/2001 | WO2001094295A1 Substituted stilbenes as glucose uptake enhancers |
| 12/13/2001 | WO2001094293A2 Benzamide ligands for the thyroid receptor |
| 12/13/2001 | WO2001094279A2 Purification of xanthophylls from marigold extracts that contain high levels of chlorophylls |
| 12/13/2001 | WO2001093921A2 Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion |
| 12/13/2001 | WO2001093917A2 Preparation for breast duct fluid collection |
| 12/13/2001 | WO2001093914A2 Multivalent platform molecules comprising high molecular weight polyethylene oxide |
| 12/13/2001 | WO2001093909A2 Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor |
| 12/13/2001 | WO2001093905A1 Immunostimulatory oligodeoxynucleotides |
| 12/13/2001 | WO2001093904A1 Method of treating gastrointestinal diseases associated with species of genus clostridium |
| 12/13/2001 | WO2001093902A2 Immunostimulatory rna/dna hybrid molecules |
| 12/13/2001 | WO2001093898A1 Methods of treating viral diseases with il-18 and il-18 combinations |
| 12/13/2001 | WO2001093891A1 Non-antibacterial tetracycline as anti-fungal agents |
| 12/13/2001 | WO2001093890A2 Botulinum toxin implant |
| 12/13/2001 | WO2001093885A1 Therapeutic agents - ii |
| 12/13/2001 | WO2001093884A1 Therapeutic agents - i |
| 12/13/2001 | WO2001093883A1 Therapeutic agents - iii |
| 12/13/2001 | WO2001093878A2 Bismuth compounds for the treatment and prevention of mucositis |
| 12/13/2001 | WO2001093877A2 Epithelial cell cancer drug |
| 12/13/2001 | WO2001093876A1 Use of n-desulfated heparin for treating or preventing inflammations |
| 12/13/2001 | WO2001093875A1 Compositions for treating biofilm |
| 12/13/2001 | WO2001093874A1 Method of treatment of obesity and paralyzed muscle and ergogenic aids |
| 12/13/2001 | WO2001093873A1 Use of aicar and related compounds |
| 12/13/2001 | WO2001093872A1 Use of organophosphorous hydroxamic acid derivatives for producing medicaments |
| 12/13/2001 | WO2001093871A1 Reangiostenosis preventives |
| 12/13/2001 | WO2001093870A1 Remedies for diseases caused by fibrin formation and/or endothelial cell damage |
| 12/13/2001 | WO2001093869A1 Sildenafil and nicotine, synergistic association for neurodegenerative diseases |
| 12/13/2001 | WO2001093868A1 Buprenorphine-containing patch |
| 12/13/2001 | WO2001093867A1 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors |
| 12/13/2001 | WO2001093866A1 Compounds with anti-hsv activity |
| 12/13/2001 | WO2001093865A2 Medicaments for treating dementia |
| 12/13/2001 | WO2001093864A1 Telomerase inhibitors and methods of their use |
| 12/13/2001 | WO2001093863A2 Pharmaceutical compositions for the treatment of depression or symptoms suggesting depression |
| 12/13/2001 | WO2001093862A1 Prostaglandin compounds for treating congestive heart failure |
| 12/13/2001 | WO2001093861A1 Tissue specific prodrug |
| 12/13/2001 | WO2001093860A1 Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
| 12/13/2001 | WO2001093859A1 Stable pharmaceutical product and formulation |
| 12/13/2001 | WO2001093858A2 Use of an aluminium and ethylenediamine-tetraacetic complex for preventing and/or treating urticaria |
| 12/13/2001 | WO2001093857A1 Composition for pain mediation and apparatus and method of use thereof |
| 12/13/2001 | WO2001093856A1 Medical composition kit for treating lesioned abnormal tissue |
| 12/13/2001 | WO2001093855A1 Skin-moistening compositions and skin-moistening foods |
| 12/13/2001 | WO2001093854A1 Method for treating hyperglycemia |
| 12/13/2001 | WO2001093853A1 Management of snoring by oral administration of dimethyl sulfone |
| 12/13/2001 | WO2001093852A2 Method of treating pain using nalbuphine and opioid antagonists |
| 12/13/2001 | WO2001093850A2 Methods and compositions using sulodexide for the treatment of diabetic nephropathy |
| 12/13/2001 | WO2001093849A2 Treatment of gastroesophageal reflux disease using piperidine derivatives |
| 12/13/2001 | WO2001093848A2 Starter kit for low dose oral contraceptives |
| 12/13/2001 | WO2001093847A2 Compositions, kits, and methods for promoting defined health benefits |
| 12/13/2001 | WO2001093846A2 Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans |
| 12/13/2001 | WO2001093845A2 Carboxyalkylether-acat inhibitor combinations |
| 12/13/2001 | WO2001093844A2 Compositions comprising a serotonin transporter inhibitor and a 5-ht1d antagonist |
| 12/13/2001 | WO2001093843A2 Benzoic acid esters having antiplasmid effect |
| 12/13/2001 | WO2001093841A2 Barbituric acid analogs as therapeutic agents |
| 12/13/2001 | WO2001093838A1 Sodium-free chondroitin |
| 12/13/2001 | WO2001093833A2 Kits and methods for optimizing the efficacy of chondroprotective compositions |
| 12/13/2001 | WO2001093832A2 Aqueous chondroprotective compositions having defined dosage requirements for efficacious delivery |
| 12/13/2001 | WO2001093831A2 Low carbohydrate compositions, kits thereof, and methods of use |
| 12/13/2001 | WO2001093830A1 Method for obtaining aqueous formulations of oxidation-sensitive active principles |
| 12/13/2001 | WO2001093828A1 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| 12/13/2001 | WO2001093827A2 Neurotoxin implant |
| 12/13/2001 | WO2001093826A1 Biocompatible synthetic polymer preparations |
| 12/13/2001 | WO2001093825A1 Storage-stable compositions of glycerol monoalkyl ethers |
| 12/13/2001 | WO2001093824A1 Use of an (r)-enantiomer of lipoic acid in cosmetics and dermatologicals |
| 12/13/2001 | WO2001093806A2 HMG CoA REDUCTASE INHIBITORS FOR PROMOTING ANGIOGENESIS |
| 12/13/2001 | WO2001093802A2 Use of riluzole or its salts for preventing and treating adrenoleukodystrophy |
| 12/13/2001 | WO2001093744A2 Controlling attention and memory by altering neuronal carbonic anhydrase activity |
| 12/13/2001 | WO2001093701A2 Aqueous chondroprotective compositions having defined ph limitations for efficacious delivery |
| 12/13/2001 | WO2001093683A1 Treating smooth muscle hyperactivity with (r)-oxybutynin and (r)- desethyloxybutynin |
| 12/13/2001 | WO2001085145A8 A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal |
| 12/13/2001 | WO2001070225A3 Oxazolidinone tablet formulation |
| 12/13/2001 | WO2001068675A3 Treatment of rosacea |
| 12/13/2001 | WO2001068147A3 Synthetic oligonucleotides as inducers of erythroid differentiation |
| 12/13/2001 | WO2001068140A3 Opioid formulations |
| 12/13/2001 | WO2001063368A3 Compliance tracking method |
| 12/13/2001 | WO2001060971A3 Method of controlling zoological and aquatic plant growth |
| 12/13/2001 | WO2001052848A3 Functional coating of linezolid microcapsules for oral administration |
| 12/13/2001 | WO2001051603A3 Pharmaceutical composition and method of using the same |
| 12/13/2001 | WO2001049276A3 Anhydrous gel comprising nsaid for topical administration to the oral cavity |
| 12/13/2001 | WO2001049275A3 Methods and compositions for mitigating pain using nitrate esters |
| 12/13/2001 | WO2001047508A3 Combination of trimebutine with an opioid analgesic |
| 12/13/2001 | WO2001046408A3 Molecular clones with mutated hiv gag/pol, siv gag and siv env genes |
| 12/13/2001 | WO2001045668A3 Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine |
| 12/13/2001 | WO2001045642A3 Pulmonary delivery of ribavirin or levovirin™ for systemic and quasi-systemic treatment of disease |
| 12/13/2001 | WO2001045637A3 Novel 4(piperazinyl (8-quinolinyl)metyl)benzamides |
| 12/13/2001 | WO2001044445A3 Human lyases and associated proteins |
| 12/13/2001 | WO2001044200A3 Selective neurokinin antagonists |
| 12/13/2001 | WO2001042262A3 Antithrombotic compound |
| 12/13/2001 | WO2001041709A3 Methods for treating cell death diseases and inflammation |
| 12/13/2001 | WO2001041701A3 The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist |
| 12/13/2001 | WO2001041550A3 Topical anesthetic formulation |
| 12/13/2001 | WO2001040243A3 Partial or full a1 agonists - n6 heterocyclic 5'-thio substituted adenosine derivatives |
| 12/13/2001 | WO2001040241A3 6-o-alkyl-2-nor-2-substituted ketolide derivatives |
| 12/13/2001 | WO2001039742A3 Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof |
| 12/13/2001 | WO2001039741A3 Mitomycin c solution |
| 12/13/2001 | WO2001037820A3 Ionizable indolinone derivatives and their use as ptk ligands |
| 12/13/2001 | WO2001037781A3 A stable aqueous dispersion of nutrients |
| 12/13/2001 | WO2001035899A3 Inhibitors of helicobacter pylori induced gastrointestinal diseases |
| 12/13/2001 | WO2001034129A3 Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use |